The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Revumenib plus azacitidine and venetoclax in older adults with NPM1-mutated or KMT2A-rearranged AML
Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the safety and efficacy of azacitidine, venetoclax, and revumenib in newly diagnosed older adults with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML) in the Beat AML Master trial (NCT03013998). The study investigated two dose levels of revumenib, finding no non-hematologic dose-limiting toxicities (DLTs) and one hematologic DLT at the first dose level. Among all evaluable patients, there was a 100% overall response rate (ORR) and a 96% composite complete remission (CRc) rate. A Phase III trial for this combination is now being planned. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting fees and/or honoraria: AbbVie, Daiichi Sankyo, Foghorn, Gilead, Novartis, Sellas, Servier, Shattuck Labs, Sumitomo Dainippon, Syndax; Research funding: AbbVie, Arog, Jazz, Gilead, Loxo, Merck, Newave, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Dainippon, Takeda, Zentalis.
